Syndax Plunges 17% on Lung Fibrosis Trial Failure as Health Care Sector Digests Mixed Signals

Syndax Pharmaceuticals fell roughly 17% after its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint of slowing lung function decline, prompting the company to abandon that indication entirely. The setback is contained to the IPF program: Syndax's approved drug Niktimvo, used in chronic graft-versus-host disease, and its cancer drug Revuforj are unaffected by the trial result.

UnitedHealth Group provided a more constructive signal for the managed-care sector, telling investors it views 2026 as the trough for Medicaid margins. The company reported third-quarter 2026 revenues of $112.7 billion, down slightly from $113.2 billion a year earlier, but net margin improved to 3.6% from 2.1% in the prior-year period, suggesting the worst of Medicaid repricing pressure may be passing. The outlook carries broader relevance for the sector as the industry braces for a Medicare Advantage reimbursement reset in 2027 that analysts expect to reshape competitive positioning across major health insurers.

On a more positive note, AbbVie reported favorable topline results from a Phase 3 study evaluating a subcutaneous induction formulation of Skyrizi, its risankizumab therapy, in patients with Crohn's disease who had previously failed at least one advanced therapy. A successful subcutaneous option could meaningfully expand Skyrizi's addressable market in inflammatory bowel disease, a segment where AbbVie has been building out its immunology franchise as a long-term successor to Humira revenues.